Annovis Bio Inc (N:ANVS)

Apr 02, 2024 07:30 am ET
Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results
Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today provided a summary of corporate updates and reported fourth quarter and full year...
Apr 01, 2024 08:00 am ET
Annovis Announces Publication That Supports Understanding of Buntanetap’s Mechanism of Action in Humans
Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today announced the publication of new data from an earlier study supporting buntanetap as a translational inhibitor...
Mar 20, 2024 07:30 am ET
Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease
Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, today announced successful completion of data cleaning for its phase II/III study of buntanetap in patients with mild...
Feb 27, 2024 08:00 am ET
Annovis Bio Announces Participation in Forum Discussion at AD/PD™ 2024
Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced panel participation in the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™...
Feb 14, 2024 07:30 am ET
Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer’s Disease
Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced last patient last visit in the phase II/III study of its lead candidate buntanetap in patients with...
Jan 30, 2024 08:00 am ET
Annovis Bio Announces the Filing of New Patent Application for Treatment of Mental Illnesses Expanding the Company’s Portfolio
Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced the filing of a patent application covering the use of buntanetap and its analogues for the treatment of...
Jan 24, 2024 08:00 am ET
Annovis Bio Refines Timeline for Parkinson’s Phase III Study Data Announcement
Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, has announced a postponement in the Phase III study data release for buntanetap in Parkinson’s Disease. This...
Dec 11, 2023 01:00 pm ET
Annovis Bio to Participate in the 139th Yale CEO Summit
Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s disease (PD) today announced its Founder, President and CEO was selected to...
Dec 05, 2023 07:30 am ET
Annovis Bio Announces Last Patient Last Visit in the Phase III Study of Buntanetap in Parkinson’s Disease
Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced last patient last visit in the phase III study of its lead candidate buntanetap in patients with early...
Dec 01, 2023 07:30 am ET
Annovis Bio Appoints Andrew Walsh as Vice President Finance
Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s disease (PD) today announced the appointment of Andrew Walsh as VP, Finance....
Nov 27, 2023 07:30 am ET
Annovis Bio Announces Full Enrollment of Its Phase II/III Alzheimer’s Disease Trial, Exceeding Original Projections
Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company addressing neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s disease (PD) and developing novel and transformative therapies, announced that AD phase II/III...
Nov 08, 2023 05:00 pm ET
Annovis Bio Announces Third Quarter 2023 Financial Results and Provides Corporate Update
Annovis Bio, Inc. (NYSE: ANVS), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including Alzheimer’s Disease (AD) and Parkinson’s Disease (PD) announced third quarter financial...
Nov 02, 2023 07:30 am ET
Annovis Bio Measures Novel Biomarkers in Plasma of Parkinson’s Patients
Recent developments in biomarker research have enabled the performance of measurements of important biomarkers in plasma rather than in CSF (cerebrospinal fluid), making it possible to follow the changes in biomarkers during the course of a neurodegenerative disease while reducing patients’ burden.
Oct 31, 2023 08:00 am ET
Annovis Bio Announces Pricing of $7.5 Million Public Offering
Annovis Bio, Inc. (NYSE: ANVS) (“Annovis”), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including Alzheimer’s Disease and Parkinson’s Disease, today announced the pricing of an underwritten public offering of 1,250,000 units consisting of (i) one share of its common stock and (ii) an accompanying warrant (each warrant to purchase one share of common stock). The combined offering price to the public of each share of common stock and accompanying warrant is $6.00.
Oct 30, 2023 04:48 pm ET
Annovis Bio Announces Launch of Proposed Public Offering
Annovis Bio, Inc. (NYSE: ANVS) (“Annovis”), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including Alzheimer’s Disease and Parkinson’s Disease, today announced a proposed underwritten public offering in which it intends to offer and sell (i) shares of its common stock and (ii) an accompanying warrant to purchase shares of common stock. The shares of common stock and the accompanying warrant will be issued separately but can only be purchased together in the offering. All of the shares of common stock and the accompanying w
Oct 30, 2023 04:42 pm ET
Annovis Bio Receives Positive Recommendation to Continue Phase 2/3 Trial of Buntanetap for Alzheimer’s Disease Patients From the Independent Data and Safety Monitoring Board (DSMB)
Annovis Bio, Inc. (NYSE: ANVS), announces the positive safety review by the Data and Safety Monitoring Board (DSMB) for its phase 2/3 trial of buntanetap, a drug candidate for moderate to mild Alzheimer’s Disease (AD) patients. The DSMB recommended that Annovis Bio continue the trial as originally designed.
Oct 24, 2023 09:13 am ET
Annovis Bio Showcases Promising Progress in Novel Drug Development at the 2023 Clinical Trials on Alzheimer's Disease Conference
Annovis Bio, Inc. (NYSE: ANVS), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), is presenting two posters at the Clinical Trials on Alzheimer's Disease (CTAD) 2023 annual conference held in Boston, Massachusetts,
Oct 12, 2023 08:02 am ET
Annovis Bio Announces Positive Interim Independent Analysis for Statistical Power in Its Alzheimer’s Study
Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced that the independent statistical group concluded that its Phase 2/3 AD study was sufficiently...
Sep 21, 2023 09:35 am ET
Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference
via InvestorWire -- Dawson James Securities, Inc. (“Dawson”), a full-service investment bank focused on emerging growth companies, today announces its 8th Annual Dawson James Small Cap Growth Conference on October 12, 2023, at the Wyndham Grand...
Jun 27, 2023 07:30 am ET
Annovis Bio Announces the Filing of a Groundbreaking Patent
Annovis Bio, Inc. (NYSE: ANVS), a clinical stage drug platform company developing novel and transformative therapies for neurodegenerative diseases, announces the creation of a novel crystalline form of buntanetap (ANVS402), and the filing of a new composition of matter provisional patent with the U.S. Patent and Trademark Office.
Jun 20, 2023 12:05 pm ET
Annovis Bio Receives Excellent Safety Rating and Positive Recommendation to Continue Phase III Trial of Buntanetap for Parkinson’s Disease Patients from the Independent Data and Safety Monitoring Boar
Annovis Bio, Inc. (NYSE: ANVS), announces the positive safety review by the Data and Safety Monitoring Board (DSMB) for its phase III trial of buntanetap, a drug for early Parkinson’s Disease (PD) patients. The DSMB recommended that Annovis Bio continue the trial as originally designed.
Jun 08, 2023 07:30 am ET
Annovis Bio Announces Completion of Phase III Parkinson's Disease Treatment Enrollment at Record Pace
BERWYN, Pa., June 8, 2023 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company addressing neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's disease (PD) and developing novel and transformative therapies, announced that its PD phase III study of its lead compound buntanetap has reached full enrollment in a record nine months after it began. 
May 11, 2023 07:00 am ET
Annovis Bio Announces First Quarter 2023 Financial Results and Provides Corporate Update
Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company addressing neurodegenerative diseases, announced first quarter financial results for the period ended March 31, 2023, and reviewed recent...
Apr 27, 2023 07:00 am ET
Annovis Bio Announces Issuance of U.S. Patent Covering the Use of Lead Drug Candidate, Buntanetap, for Prevention or Treatment of Disease States Due to Metal Dis-Homeostasis in Healthy or Sick Humans
(NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing treatments for neurodegenerative diseases announced today that the United States Patent and Trademark Office (USPTO) has granted the Company a patent with...
Apr 20, 2023 07:00 am ET
ANNOVIS BIO PROVIDES UPDATED WEBCAST LINK AND DIAL-IN INFORMATION FOR TODAY'S R&D WEBCAST
Company to hold R&D webcast today at 4:00 pm ET to review ongoing clinical programs in Alzheimer's disease and Parkinson's disease
Apr 19, 2023 07:30 am ET
ANNOVIS BIO ANNOUNCES UPDATE ON RECRUITMENT INTO ITS PHASE 2/3 ALZHEIMER'S STUDY AND UPCOMING R&D WEBCAST
Phase 2/3 AD Study continues to make steady progress in patient recruitment
Apr 13, 2023 07:30 am ET
Apr 11, 2023 09:04 am ET
ANNOVIS BIO RAISES AGGREGATE GROSS PROCEEDS OF APPROXIMATELY $8.7 MILLION
BERWYN, Pa., April 11, 2023 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced that in the last week it has raised aggregate gross proceeds of approximately $8.7 million between its now-terminated at–the-market program and a private placement to individual members of its Board of Directors and management.
Apr 03, 2023 07:30 am ET
ANNOVIS BIO ANNOUNCES FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
BERWYN, Pa., April 3, 2023 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, has announced fourth quarter and full year financial results for the period ended December 31, 2022, and reviewed recent accomplishments.
Mar 22, 2023 07:30 am ET
ANNOVIS BIO ANNOUNCES TWO PRESENTATIONS AT THE AD/PD™ 2023 INTERNATIONAL CONFERENCE ON ALZHEIMER'S AND PARKINSON'S DISEASES
BERWYN, Pa., March 22, 2023 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced the Company will be making two presentations at the upcoming AD/PD™ 2023 International Conference on Alzheimer's and Parkinson's Disease, which is taking place from March 28 through April 1, 2023, in Gothenburg, Sweden.
Feb 08, 2023 06:30 am ET
Feb 01, 2023 06:30 am ET
Annovis Bio Announces Filing of Patent Covering the Administration of Buntanetap and Its Analogues for the Treatment of Mental Illnesses
BERWYN, Pa., Feb. 1, 2023 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's and Parkinson's disease announced today the filing of a patent application that extends the breadth of its platform from neurodegenerative to neuropsychiatric indications: "Treatment of mental illness via administration of buntanetap and analogues."
Jan 25, 2023 06:30 am ET
ANNOVIS BIO ANNOUNCES PATIENT ENROLLMENT UPDATE FOR PHASE 3 STUDY OF BUNTANETAP FOR THE TREATMENT OF PARKINSON'S DISEASE
Strong enrollment in Phase 3 trial demonstrates continued executionInterim analysis expected in 2Q 2023
Jan 06, 2023 06:30 am ET
Annovis Bio Announces New Appointments to Strengthen Its Senior Leadership Team
BERWYN, Penn., Jan. 6, 2023 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced key additions to its senior leadership team with the appointments of Dr. Michael Christie as Vice President of Process Chemistry and David Prohaska as Vice President of Toxicology and Pharmacology.
Nov 08, 2022 04:35 pm ET
Annovis Bio Announces Third Quarter 2022 Results and Provides Corporate Update
BERWYN, Penn., Nov. 8, 2022 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced third quarter financial results for the quarter ended September 30, 2022, and reviewed recent accomplishments.
Oct 20, 2022 07:30 am ET
Annovis Bio to Present at the 2022 ThinkEquity Investor Conference
BERWYN, Pa., Oct. 20, 2022 /PRNewswire/ -- (NYSE: ANVS) Annovis Bio ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, announced today that it will present at the ThinkEquity 2022 Investor Conference on Wednesday, October 26, 2022, in New York City.
Oct 11, 2022 07:30 am ET
Annovis Bio Announces Publication of Phase 2a Clinical Data in The Journal of Prevention of Alzheimer's Disease
BERWYN, Pa., Oct. 11, 2022 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company addressing neurodegenerative diseases, today announced the publication of Phase 2a clinical study data in The Journal of Prevention of Alzheimer's Disease.
Oct 06, 2022 07:30 am ET
Annovis Bio Announces FDA Authorization to Proceed with Phase 2/3 Trial for Buntanetap in Alzheimer's Disease
BERWYN, Pa., Oct. 6, 2022 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company addressing neurodegenerative diseases, announced today that the U.S. Food and Drug Administration (FDA) has authorized the Phase 2/3 clinical study of buntanetap in moderate Alzheimer's Disease (AD).
Sep 29, 2022 07:30 am ET
Annovis Bio to Present at the 2022 Ladenburg Thalmann Healthcare Conference
BERWYN, Pa., Sept. 29, 2022 /PRNewswire/ -- (NYSE: ANVS) Annovis Bio ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, announced today that it will present at the Ladenburg Thalmann 2022 Healthcare Conference on Thursday, September 29, 2022, in New York City.
Sep 13, 2022 07:30 am ET
Annovis Bio Announces Publication of Patents Covering the Treatment of Amyloid Lateral Sclerosis, Huntington's Disease and Prion Diseases
BERWYN, Pa., Sept. 13, 2022 /PRNewswire/ -- (NYSE: ANVS) Annovis Bio ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, announced today the publication of three granted US patents – US11400075 (link), US11376238 (link), and US11382893 (link). The patents cover methods of treating amyloid lateral sclerosis (ALS), Huntington's disease, and prion diseases by administering buntanetap. They will provide intellectual property protection through 2031, prior to any patent extensions.
Sep 08, 2022 07:30 am ET
Annovis Bio's CEO Maria Maccecchini Issues Letter to Stockholders
BERWYN, Pa., Sept. 8, 2022 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company addressing neurodegenerative diseases, today released the following letter to stockholders from its Chief Executive Officer Dr. Maria Maccecchini.
Aug 29, 2022 04:00 pm ET
Annovis Bio Appoints Henry Hagopian III as Chief Financial Officer
BERWYN, Pa., Aug. 29, 2022 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, announced the appointment of Henry Hagopian III as Chief Financial Officer, effective immediately.  Mr. Hagopian comes to Annovis with 30 years of finance and accounting experience, including 15 years of increasing responsibility at Organogenesis, a leading publicly-traded regenerative medicine company.  The company has also announced that Jeff McGroarty has stepped away from his role as Chief Financial Officer t
Aug 24, 2022 07:30 am ET
Annovis Bio Announces First Patient Dosed in Phase 3 Trial in Patients with Early Parkinson's Disease
BERWYN, Pa., Aug. 24, 2022 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company addressing neurodegenerative diseases, announced today that the first patient in the Phase 3 clinical trial evaluating buntanetap in early Parkinson's Disease (PD) has been dosed.
Aug 08, 2022 07:30 am ET
Annovis Bio Announces Second Quarter 2022 Results and Provides Corporate Update
BERWYN, Pa., Aug. 8, 2022 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced second quarter financial results for the quarter ended June 30, 2022, and reviewed recent accomplishments.
Aug 01, 2022 07:30 am ET
Annovis Bio to Participate on Alzheimer's Association International Conference Panel
The Panel will be Moderated by Jeffrey Cummings, MD, ScD, and Krista Lanctôt, Ph.D.
Jul 14, 2022 07:30 am ET
Annovis Bio to Present at the Alzheimer's Association International Conference
Maria Maccecchini, Ph.D., Founder, President, and CEO, will be participating on a panel discussing the Systems Biology of Alzheimer's Disease moderated by Jeffrey Cummings, MD, ScD, and Krista Lanctôt, Ph.D.
Jun 09, 2022 08:30 am ET
Annovis Bio Submits an International Patent Application to Cover the Treatment of Neurological Injuries Caused by Infections
Annovis Bio's Current Intellectual Property Portfolio Covers the Use of Buntanetap, the Company's Lead Compound, to Treat Neurodegenerative Diseases
May 04, 2022 08:30 am ET
Annovis Bio Announces First Quarter 2022 Results and Provides Corporate Update
Berwyn, Pennsylvania--(Newsfile Corp. - May 4, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced first quarter financial results for the quarter ended March 31, 2022, and provided a corporate update.
Apr 28, 2022 04:30 pm ET
Apr 26, 2022 07:15 am ET
Lantern Pharma's Board of Directors Names Maria Maccecchini, Ph.D. as a Director Nominee to Lantern's Board of Directors
DALLAS, April 26, 2022 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (A.I.) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that Maria L. Maccecchini, Ph.D. has been named as a nominee for election to Lantern's Board of Directors. Dr. Maccecchini will be presented alongside a slate of five existing Directors at Lantern's upcoming Annual Meeting to be held on June 8, 2022.
Apr 11, 2022 08:30 am ET
Annovis Bio to Participate in World Parkinson's Day to Raise Awareness on the Debilitating Disease
Berwyn, Pennsylvania--(Newsfile Corp. - April 11, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, is pleased to participate in World Parkinson's Day to promote greater awareness of how Parkinson's disease affects those living with the progressive disease and support research efforts to develop disease-modifying treatment options.
Mar 23, 2022 08:30 am ET
Annovis Bio to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest
Berwyn, Pennsylvania--(Newsfile Corp. - March 23, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced the company has been invited to present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, on March 28th - 30th.
Mar 18, 2022 08:30 am ET
Annovis Bio Presents at International Conference on Alzheimer's & Parkinson (AD/PD 2022)
Company Provides Update on Clinical Trial Design of Upcoming Phase 3 Clinical Trials in Parkinson's Disease on March 20, 2022
Mar 08, 2022 08:30 am ET
Annovis Bio Announces Presentation at International Conference on Alzheimer's & Parkinson's Diseases 2022
Presentation will Showcase Trial Design in Upcoming Phase 3 Trial in Parkinson's Disease
Mar 03, 2022 08:30 am ET
Annovis Bio to Present at the Cowen 42nd Annual Health Care Conference
Berwyn, Pennsylvania--(Newsfile Corp. - March 3, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced the company will be participating in the upcoming Cowen 42nd Annual Health Care Conference.
Jan 25, 2022 09:00 am ET
Annovis Bio Announces Positive FDA Feedback for Buntanetap Phase 3 Clinical Development in Parkinson's Disease
FDA gives guidance for two Phase 3 clinical trials of Buntanetap in Parkinson's Disease
Jan 10, 2022 08:30 am ET
Annovis Bio Enhances Leadership Team with Two Senior Appointments
Berwyn, Pennsylvania--(Newsfile Corp. - January 10, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced the appointment of Eve Damiano, MS, RAC, as its new Senior Vice President of Regulatory Operations, and the promotion of Cheng Fang, Ph.D., to Senior Vice President of Research & Development, as of January 1, 2022.
Jan 05, 2022 08:30 am ET
Annovis Bio Announces Official Unique Name Buntanetap for Lead Candidate ANVS401
Berwyn, Pennsylvania--(Newsfile Corp. - January 5, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced that the United States Adopted Names (USAN) Council has assigned the unique name "Buntanetap" for the Company's lead drug candidate ANVS401/Posiphen. Buntanetap, a translational inhibitor of neurotoxic proteins, is currently under clinical development in Alzheimer's disease (AD), Parkinson's disease (PD), and dementia in Down syndrome (AD-DS).
Jan 03, 2022 08:30 am ET
Annovis Bio to Participate in the Biotech Showcase and H.C. Wainwright Bioconnect Virtual Conferences
Company to Conduct Virtual One-on-One Meetings During Biotech Showcase
Dec 20, 2021 08:30 am ET
Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders
Berwyn, Pennsylvania--(Newsfile Corp. - December 20, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today released the following letter to stockholders from its Chief Executive Officer, Dr. Maria Maccecchini.
Dec 14, 2021 08:29 am ET
Annovis Bio Announces Publication of ANVS401 Mechanism of Action in Peer-Reviewed Pharmaceutics
ANVS401 (Posiphen) Inhibits the Translation of mRNAs of Neurotoxic Proteins Responsible for the Progression of Neurodegenerative Diseases
Nov 15, 2021 09:00 am ET
Annovis Bio Announces Transfer of Listing to the New York Stock Exchange
Trading to begin November 18, 2021 with current ticker "ANVS"
Nov 12, 2021 10:26 am ET
Annovis Bio Presented At The 14th Clinical Trials on Alzheimer's Disease Conference
With additional data, the primary, secondary, and exploratory endpoints were met in Phase 2a study
Nov 09, 2021 08:30 am ET
Annovis Bio Presents Poster on Mechanism of Action at the 14th Clinical Trials on Alzheimer's Disease (CTAD) Conference
Poster highlighting the mechanism of action for ANVS401 is on display onsite and online
Nov 03, 2021 10:43 am ET
SHAREHOLDER ALERT: Robbins LLP Investigates Annovis Bio, Inc. (ANVS) for Misleading Shareholders
Shareholder rights law firm Robbins LLP is investigating Annovis Bio, Inc. (NYSE: ANVS) to determine whether certain Annovis officers and directors violated the Securities Exchange Act of 1934. Annovis is a clinical stage pharmaceutical company. Its lead compound is ANVS401 (Posiphen), which purportedly inhibited the synthesis of n
Nov 02, 2021 08:30 am ET
Annovis Bio to Present at the 14th Clinical Trials on Alzheimer's Disease (CTAD) Conference
Berwyn, Pennsylvania--(Newsfile Corp. - November 2, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative diseases, today announced that the Company's representatives will give both an oral and poster presentation at the 14th Clinical Trials on Alzheimer's Disease conference (CTAD) hosted in-person and virtually at the Boston Park Plaza, Boston, MA from November 9-12, 2021.
Oct 15, 2021 09:00 pm ET
ANNOVIS DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Annovis Bio, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Annovis Bio, Inc. (“Annovis” or the “Company”) (NYSE: ANVS) in the United States District Court for the Eastern District of Pennsylvania on behalf of all persons and entities who purchased or otherwise acquired Annovis securities between May 21, 2021 and July 28, 2021, both dates inclusive (the “Class Period”). Investors have until October 18, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Oct 15, 2021 08:56 pm ET
SHAREHOLER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Annovis Bio, Inc. of Class Action Lawsuit and Upcoming Deadline - ANVS
NEW YORK, Oct. 15, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Annovis Bio, Inc. ("Annovis" or the "Company") (NYSE: ANVS) and certain of its officers.  The class action, filed in the United States District Court for the Eastern District of Pennsylvania, and docketed under 21-cv-04040, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Annovis securities between May 21, 2021 and July 28, 2021, inclusive (the "Class Period").  Plaintiff pursues claims against the Defendan
Oct 14, 2021 01:11 pm ET
Deadline in 4 Days: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Class Action Lawsuit Against Annovis Bio, Inc. (ANVS)
The law firm of Kessler Topaz Meltzer & Check, LLP reminds Annovis Bio, Inc. (NYSE:   ANVS) (“Annovis”) investors that a securities fraud class action lawsuit has been filed in the United States District Court for the Eastern District of...
Oct 13, 2021 10:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Annovis Bio, Cassava Sciences, The Honest Company, and Hyzon Motors and Encourages Investors to Contact
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Annovis Bio, Inc. (NYSE: ANVS), Cassava Sciences, Inc. (NASDAQ: SAVA), The...
Oct 13, 2021 10:20 am ET
Kessler Topaz Meltzer & Check, LLP: Important Deadline Reminder for Annovis Bio, Inc. Investors in Securities Fraud Class Action Lawsuit
RADNOR, Pa., Oct. 13, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed against Annovis Bio, Inc. (NYSE: ANVS) ("Annovis") on behalf of those who purchased or acquired Annovis securities betweeen May 21, 2021 and July 28, 2021, inclusive (the "Class Period").
Oct 12, 2021 10:49 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of ANVS, PYPL, SESN and SLQT
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. SelectQuote, Inc. (SLQT)Class Period: May 20, 2020 and August 25, 2021, or shares issued pursuant to the May 2020...
Oct 12, 2021 01:38 pm ET
ANVS MONDAY DEADLINE: ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Annovis Bio, Inc. Investors to Secure Counsel Before Important October 18 Deadline in Securities Class Action – ANVS
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Annovis Bio, Inc. (NYSE: ANVS) between May 21, 2021 and July 28, 2021, inclusive (the “Class Period”), of the important October 18, 2021 lead plaintiff...
Oct 12, 2021 12:15 pm ET
DEADLINE ALERT for ANVS, VIEW, and SESN: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Oct 11, 2021 10:47 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS ANVS, BMY, HNST, PYPL INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Annovis Bio, Inc. (ANVS)Class Period: 5/21/2021 -...
Oct 11, 2021 11:00 am ET
ANVS Upcoming Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Annovis Bio, Inc. Shareholders of Class Action and Lead Plaintiff Deadline: October 18, 2021
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Annovis Bio, Inc. (“Annovis” or the “Company”) (NYSE: ANVS) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Annovis securities between May 21, 2021 and July 28, 2021, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site:
Oct 08, 2021 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS ANVS, PYPL, SESN, SLQT INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Annovis Bio, Inc. (ANVS)Class Period: 5/21/2021 - 7/28/2021Lead Plaintiff Motion Deadline: October 18,...
Oct 08, 2021 05:04 pm ET
Annovis Bio, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm
The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Annovis Bio, Inc. (NYSE : ANVS) investors that acquired shares between May 21, 2021 and July 28, 2021. Investors have until October 18, 2021 to seek an...
Oct 08, 2021 01:00 pm ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Annovis Bio, Inc. (ANVS)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming October 18, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Annovis Bio, Inc. (“Annovis” or the...
Oct 07, 2021 10:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Annovis Bio, Cassava Sciences, The Honest Company, and Hyzon and Encourages Investors to Contact the Fi
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Annovis Bio, Inc. (NYSE: ANVS), Cassava Sciences, Inc. (NASDAQ: SAVA), The...
Oct 07, 2021 07:45 pm ET
SHAREHOLER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Annovis Bio, Inc. of Class Action Lawsuit and Upcoming Deadline - ANVS
NEW YORK, Oct. 7, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Annovis Bio, Inc. ("Annovis" or the "Company") (NYSE: ANVS) and certain of its officers. The class action, filed in the United States District Court for the Eastern District of Pennsylvania, and docketed under 21-cv-04040, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Annovis securities between May 21, 2021 and July 28, 2021, inclusive (the "Class Period"). Plaintiff pursues claims against the Defendants
Oct 07, 2021 06:10 pm ET
CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Annovis Bio, Inc. Shareholders of Securities Fraud Class Action Lawsuit
The law firm of Kessler Topaz Meltzer & Check, LLP reminds Annovis Bio, Inc. (NYSE: ANVS) (“Annovis”) investors that a securities fraud class action lawsuit has been filed in the United States District Court for the Eastern District of Pennsylvania...
Oct 06, 2021 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS ANVS, HNST, WDH INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Annovis Bio, Inc. (ANVS)Class Period: 5/21/2021 -...
Oct 06, 2021 04:27 pm ET
INVESTOR ALERT: Kirby McInerney LLP Reminds Investors That a Securities Class Action Lawsuit Has Been Filed on Behalf of Annovis Bio, Inc. (ANVS) Investors and Encourages Investors to Contact the Firm
The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Eastern District of Pennsylvania on behalf of those who acquired Annovis Bio, Inc. (“Annovis” or the “Company”)...
Oct 06, 2021 10:00 am ET
SLQT, ANVS & VIEW - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Actions and Deadlines
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Oct 05, 2021 11:23 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of ANVS, PYPL, SAVA and SESN
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. Annovis Bio, Inc. (ANVS)Class Period: May 21, 2021 and July 28, 2021Lead Plaintiff Motion Deadline: October 18,...
Oct 05, 2021 05:31 pm ET
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Annovis Bio, Inc. Investors with Losses to Secure Counsel Before Important October 18 Deadline in Securities Class Action – ANVS
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Annovis Bio, Inc. (NYSE: ANVS) between May 21, 2021 and July 28, 2021, inclusive (the “Class Period”), of the important October 18, 2021 lead plaintiff...
Oct 05, 2021 01:00 pm ET
DEADLINE ALERT for ATIP, SLQT, PHG, ANVS: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Oct 05, 2021 11:35 am ET
DEADLINE ALERT for ANVS, VIEW, and SESN: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Oct 05, 2021 08:00 am ET
Annovis Bio Announces Positive Phase 2 Efficacy Data for the Treatment of Parkinson's Disease
Berwyn, Pennsylvania--(Newsfile Corp. - October 5, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced results from the completed dose response Phase 2 clinical trial of ANVS401 in 54 PD patients, which found that once-daily ANVS401 was superior to placebo in improving motor function.
Oct 04, 2021 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS ANVS, PYPL, SESN, WDH INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Annovis Bio, Inc. (ANVS)Class Period: 5/21/2021 - 7/28/2021Lead Plaintiff Motion Deadline: October 18,...
Oct 04, 2021 05:45 pm ET
ANVS SHAREHOLDER CLASS ACTION LAWSUIT DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Annovis Bio, Inc.
NEW YORK, Oct. 4, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit filed on behalf of investors who purchased or acquired the securities of Annovis Bio, Inc.. ("Annovis Bio" or the "Company") (NYSE: ANVS) from May 21, 2021 through July 28, 2021 (the "Class Period"). The lawsuit filed in the United States District Court for the Eastern District of Pennsylvania alleges violations of the Securities Act of 1934.
Oct 04, 2021 03:13 pm ET
(ANVS) DEADLINE: Did You Suffer a Substantial Loss? Contact Johnson Fistel About Leading Annovis Bio Class Action Lawsuit
Shareholder rights law firm Johnson Fistel, LLP announces that purchasers of Annovis Bio, Inc. ("Annovis” or the "Company") (NYSE: ANVS) between May 21, 2021 and July 28, 2021(the “Class Period”) have until October 18, 2021, to file a lead...
Oct 04, 2021 09:12 am ET
ANVS Investor Reminder: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Annovis Bio, Inc.
RADNOR, Pa., Oct. 4, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed against Annovis Bio, Inc. (NYSE: ANVS) ("Annovis") on behalf of those who purchased or acquired Annovis securities betweeen May 21, 2021 and July 28, 2021, inclusive (the "Class Period").
Oct 03, 2021 07:46 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Annovis Bio, Inc. of Class Action Lawsuit and Upcoming Deadline – ANVS
Pomerantz LLP announces that a class action lawsuit has been filed against Annovis Bio, Inc. (“Annovis” or the “Company”) (NYSE: ANVS) and certain of its officers.   The class action, filed in the United States District Court for the Eastern...
Oct 02, 2021 08:00 am ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Annovis Bio, Cassava Sciences, and The Honest Company and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Annovis Bio, Inc. (NYSE: ANVS), Cassava Sciences, Inc. (NASDAQ: SAVA), and The...
Oct 01, 2021 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS ANVS, PYPL, SAVA, SESN INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Annovis Bio, Inc. (ANVS)Class Period: 5/21/2021...
Oct 01, 2021 01:15 pm ET
ANVS INVESTOR CLASS ACTION DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Annovis Bio, Inc.
Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit filed on behalf of investors who purchased or acquired the securities of...
Oct 01, 2021 11:35 am ET
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Annovis Bio, Inc. (ANVS) Investors
LOS ANGELES, Oct. 1, 2021 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Annovis Bio, Inc. ("Annovis" or the "Company") (NYSE: ANVS) securities between May 21, 2021 and July 28, 2021, inclusive (the "Class Period"). Annovis investors have until October 18, 2021 to file a lead plaintiff motion.
Sep 30, 2021 12:30 pm ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Annovis Bio, Inc. (ANVS)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming October 18, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Annovis Bio, Inc. (“Annovis” or the...
Sep 30, 2021 08:25 am ET
Important Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Annovis Bio, Inc. Investors of Deadline in Securities Fraud Class Action Lawsuit
The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States District Court for the Eastern District of Pennsylvania against Annovis Bio, Inc. (NYSE: ANVS) (“Annovis”)...
Sep 29, 2021 09:39 pm ET
ANVS, PYPL, SESN, WDH INVESTOR ALERT: CLAIMSFILER REMINDS SHAREHOLDERS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Annovis Bio, Inc. (ANVS)Class Period: 5/21/2021 - 7/28/2021Lead Plaintiff Motion Deadline: October 18,...
Sep 29, 2021 09:23 pm ET
SHAREHOLER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Annovis Bio, Inc. of Class Action Lawsuit and Upcoming Deadline - ANVS
NEW YORK, Sept. 29, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Annovis Bio, Inc. ("Annovis" or the "Company") (NYSE: ANVS) and certain of its officers. The class action, filed in the United States District Court for the Eastern District of Pennsylvania, and docketed under 21-cv-04040, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Annovis securities between May 21, 2021 and July 28, 2021, inclusive (the "Class Period"). Plaintiff pursues claims against the Defendant
Sep 29, 2021 12:35 pm ET
DEADLINE ALERT for ANVS, VIEW, and SESN: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Sep 29, 2021 11:00 am ET
DEADLINE ALERT for ATIP, SLQT, PHG, ANVS: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Sep 28, 2021 10:25 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of ANVS, SESN and WDH
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. Annovis Bio, Inc. (ANVS)Class Period: May 21, 2021 and July 28, 2021Lead Plaintiff Motion Deadline: October 18,...
Sep 28, 2021 05:00 pm ET
ROSEN, A TOP RANKED LAW FIRM, Encourages Annovis Bio, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important October 18 Deadline in Securities Class Action – ANVS
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Annovis Bio, Inc. (NYSE: ANVS) between May 21, 2021 and July 28, 2021, inclusive (the “Class Period”), of the important October 18, 2021 lead plaintiff...
Sep 27, 2021 10:54 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS ANVS, PYPL, SESN INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Annovis Bio, Inc. (ANVS)Class Period: 5/21/2021 -...
Sep 27, 2021 09:13 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Zymergen, Annovis Bio, and Cassava Sciences and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Zymergen Inc. (NASDAQ: ZY), Annovis Bio, Inc. (NYSE: ANVS), and Cassava...
Sep 25, 2021 06:24 pm ET
Deadline Alert: Kessler Topaz Meltzer & Check, LLP Alerts Investors of Lead Plaintiff Deadline in Securities Fraud Class Action Lawsuit Against Annovis Bio, Inc.
RADNOR, Pa., Sept. 25, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP reminds Annovis Bio, Inc. (NYSE: ANVS) ("Annovis") investors that a securities fraud class action lawsuit has been on behalf of those who purchased or acquired Annovis securities betweeen May 21, 2021 and July 28, 2021, inclusive (the "Class Period").
Sep 25, 2021 10:17 am ET
(ANVS) DEADLINE: Did You Suffer a Substantial Loss? Contact Johnson Fistel Regarding Leading Annovis Bio Class Action Lawsuit
SAN DIEGO, Sept. 25, 2021 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP announces that purchasers of Annovis Bio, Inc. ("Annovis" or the "Company") (NYSE: ANVS) between May 21, 2021 and July 28, 2021(the "Class Period") have until October 18, 2021, to file a lead plaintiff motion. 
Sep 24, 2021 10:50 pm ET
ANVS, PYPL, SAVA, SESN INVESTOR ALERT: CLAIMSFILER REMINDS SHAREHOLDERS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Annovis Bio, Inc. (ANVS)Class Period: 5/21/2021 - 7/28/2021Lead Plaintiff Motion Deadline: October 18,...
Sep 24, 2021 10:00 am ET
SLQT, ANVS & VIEW - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Actions and Deadlines
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Sep 24, 2021 09:00 am ET
Annovis Bio to Present at the Cantor Global Healthcare Conference
Dr. Maria Maccecchini will present a corporate update on Tuesday, September 28 at 11:20am ET
Sep 23, 2021 07:49 pm ET
SHAREHOLER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Annovis Bio, Inc. of Class Action Lawsuit and Upcoming Deadline – ANVS
Pomerantz LLP announces that a class action lawsuit has been filed against Annovis Bio, Inc. (“Annovis” or the “Company”) (NYSE: ANVS) and certain of its officers.   The class action, filed in the United States District Court for the Eastern...
Sep 23, 2021 01:00 pm ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Annovis Bio, Inc. (ANVS)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming October 18, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Annovis Bio, Inc. (“Annovis” or the...
Sep 22, 2021 10:50 pm ET
INVESTOR ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action Lawsuits filed on behalf of ANVS, PYPL, SAVA, SESN Investors, Lead Plaintiff Deadlines Set
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Annovis Bio, Inc. (ANVS)Class Period: 5/21/2021...
Sep 22, 2021 09:08 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Zymergen, Annovis Bio, and Cassava Sciences and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Zymergen Inc. (NASDAQ: ZY), Annovis Bio, Inc. (NYSE: ANVS), and Cassava...
Sep 22, 2021 04:15 pm ET
ANVS SHAREHOLDER CLASS ACTION DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Annovis Bio, Inc.
Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit filed on behalf of investors who purchased or acquired the securities of...
Sep 22, 2021 11:45 am ET
DEADLINE ALERT for ANVS, VIEW, and SESN: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Sep 22, 2021 11:00 am ET
DEADLINE ALERT for ATIP, SLQT, PHG, ANVS: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Sep 21, 2021 10:32 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of ANVS, PYPL and SESN
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. Annovis Bio, Inc. (ANVS)Class Period: May 21, 2021 and July 28, 2021Lead Plaintiff Motion Deadline: October 18,...
Sep 21, 2021 04:00 pm ET
ANVS DEADLINE REMINDER: Kessler Topaz Meltzer & Check, LLP – Important October 18, 2021 Deadline Reminder for Annovis Bio, Inc. Investors
The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States District Court for the Eastern District of Pennsylvania against Annovis Bio, Inc. (NYSE: ANVS) (“Annovis”)...
Sep 21, 2021 03:50 pm ET
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Annovis Bio, Inc. Investors to Secure Counsel Before Important October 18 Deadline in Securities Class Action – ANVS
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Annovis Bio, Inc. (NYSE: ANVS) between May 21, 2021 and July 28, 2021, inclusive (the “Class Period”), of the important October 18, 2021 lead...
Sep 21, 2021 03:23 pm ET
INVESTOR ALERT: Kirby McInerney LLP Reminds Investors That a Securities Class Action Lawsuit Has Been Filed on Behalf of Annovis Bio, Inc. (ANVS) Investors and Encourages Investors to Contact the Firm
The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Eastern District of Pennsylvania on behalf of those who acquired Annovis Bio, Inc. (“Annovis” or the “Company”) (NYSE:
Sep 20, 2021 10:47 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS ANVS, PYPL, SAVA, SESN INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Annovis Bio, Inc. (ANVS)Class Period: 5/21/2021 - 7/28/2021Lead Plaintiff Motion Deadline: October 18,...
Sep 19, 2021 10:33 pm ET
SHAREHOLER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Annovis Bio, Inc. of Class Action Lawsuit and Upcoming Deadline - ANVS
NEW YORK, Sept. 19, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Annovis Bio, Inc. ("Annovis" or the "Company") (NYSE: ANVS) and certain of its officers. The class action, filed in the United States District Court for the Eastern District of Pennsylvania, and docketed under 21-cv-04040, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Annovis securities between May 21, 2021 and July 28, 2021, inclusive (the "Class Period"). Plaintiff pursues claims against the Defendant
Sep 17, 2021 10:00 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS ANVS, PYPL, SESN INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Annovis Bio, Inc. (ANVS)Class Period: 5/21/2021 -...
Sep 16, 2021 11:35 am ET
DEADLINE ALERT for ANVS, VIEW, and SESN: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Sep 16, 2021 11:30 am ET
DEADLINE ALERT for ATIP, SLQT, PHG, ANVS: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Sep 15, 2021 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS ANVS, ATVI, SAVA, ZY, INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Activision Blizzard, Inc. (ATVI)Class Period: 8/4/2016 - 7/27/2021Lead Plaintiff Motion Deadline:...
Sep 15, 2021 08:58 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Coinbase, Annovis Bio, and Spectrum and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Coinbase Global Inc. (NASDAQ: COIN), Annovis Bio, Inc. (NYSE: ANVS), and...
Sep 15, 2021 07:28 pm ET
Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Filed Against Annovis Bio, Inc.
RADNOR, Pa., Sept. 15, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors of Annovis Bio, Inc. (NYSE: ANVS) ("Annovis") that a securities fraud class action lawsuit has been filed on behalf of those who purchased or acquired Annovis securities betweeen May 21, 2021 and July 28, 2021, inclusive (the "Class Period").
Sep 15, 2021 09:00 am ET
SHAREHOLDER ALERT: Robbins LLP Announces that Annovis Bio, Inc. (ANVS) is Being Sued for Misleading Shareholders
Shareholder rights law firm Robbins LLP announces that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Annovis Bio, Inc. (NYSE: ANVS) securities between May 21, 2021 and July 28, 2021, for violations of the Securities Exchange Act of 1934. Annovis is a clinical stage pharmaceutical compa
Sep 14, 2021 10:50 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of ANVS, COIN, PYPL and SESN
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. Coinbase Global Inc. (COIN)Class Period: Purchase of shares issued in connection with the April 2021 Direct...
Sep 14, 2021 12:08 pm ET
Portnoy Law: Lawsuit Filed On Behalf of Annovis Bio, Inc. Investors
The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Annovis Bio, Inc. ("Annovis" or "the Company") (NYSE : ANVS) investors that acquired securities between May 21, 2021 and July 28, 2021. Investors are...
Sep 14, 2021 12:00 pm ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Annovis Bio, Inc. (ANVS)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming October 18, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Annovis Bio, Inc. (“Annovis” or the...
Sep 13, 2021 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS ANVS, PYPL, SESN, ZY INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Zymergen Inc. (ZY)Class Period: purchase of shares...
Sep 13, 2021 06:30 pm ET
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Annovis Bio, Inc. Investors with Losses to Secure Counsel Before Important October 18 Deadline in Securities Class Action – ANVS
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Annovis Bio, Inc. (NYSE: ANVS) between May 21, 2021 and July 28, 2021, inclusive (the “Class Period”), of the important October 18, 2021 lead plaintiff...
Sep 13, 2021 04:31 pm ET
ANVS SHAREHOLDER CLASS ACTION DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Annovis Bio, Inc.
Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit filed on behalf of investors who purchased or acquired the securities of...
Sep 13, 2021 11:10 am ET
Pomerantz Law Firm Announces the Filing of a Class Action Against Annovis Bio, Inc. and Certain Officers - ANVS
NEW YORK, Sept. 13, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Annovis Bio, Inc. ("Annovis" or the "Company") (NYSE: ANVS) and certain of its officers. The class action, filed in the United States District Court for the Eastern District of Pennsylvania, and docketed under 21-cv-04040, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Annovis securities between May 21, 2021 and July 28, 2021, inclusive (the "Class Period"). Plaintiff pursues claims against the Defendant
Sep 13, 2021 11:00 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Annovis Bio, Inc. (ANVS)
LOS ANGELES, Sept. 13, 2021 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming October 18, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Annovis Bio, Inc. ("Annovis" or the "Company") (NYSE: ANVS) securities between May 21, 2021 and July 28, 2021, inclusive (the "Class Period").
Sep 13, 2021 10:00 am ET
SLQT, ANVS & VIEW - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Actions and Deadlines
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Sep 12, 2021 10:01 am ET
ANVS EQUITY ALERT: Kessler Topaz Meltzer & Check, LLP Announces that a Securities Fraud Class Action Lawsuit was filed on Behalf of Investors of Annovis Bio, Inc.
The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States District Court for the Eastern District of Pennsylvania against Annovis Bio, Inc. (NYSE: ANVS) (“Annovis”)...
Sep 10, 2021 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS ATVI, ZY, ANVS, SESN INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Activision Blizzard, Inc. (ATVI)Class Period: 8/4/2016 - 7/27/2021Lead Plaintiff Motion Deadline:...
Sep 10, 2021 10:00 am ET
DEADLINE ALERT for SLQT, PHG, ANVS, VIEW: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Sep 10, 2021 09:00 am ET
Annovis Bio to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
BERWYN, Pa., Sept. 10, 2021 /PRNewswire/ -- Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced CEO Maria L. Maccecchini will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually from September 13 – 15, 2021. 
Sep 09, 2021 08:07 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Annovis Bio, Inc. - ANVS
Pomerantz LLP is investigating claims on behalf of investors of Annovis Bio, Inc. (“Annovis” or the “Company”) (NYSE: ANVS).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Sep 09, 2021 01:00 pm ET
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Annovis Bio, Inc. (ANVS)
BENSALEM, Pa., Sept. 9, 2021 /PRNewswire/ -- Law Offices of Howard G. Smith reminds investors of the upcoming October 18, 2021 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Annovis Bio, Inc. ("Annovis" or the "Company") (NYSE: ANVS) securities between May 21, 2021 and July 28, 2021, inclusive (the "Class Period").
Sep 09, 2021 11:05 am ET
DEADLINE ALERT for ANVS, VIEW, and SESN: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Sep 08, 2021 09:42 pm ET
ANVS, ATVI, SESN, ZY SHAREHOLDERS - ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action lawsuits filed on behalf of Investors, Lead Plaintiff Deadlines Set
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Activision Blizzard, Inc. (ATVI)Class Period:...
Sep 08, 2021 09:04 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Coinbase, Annovis Bio, and Spectrum and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Coinbase Global Inc. (NASDAQ: COIN), Annovis Bio, Inc. (NYSE: ANVS), and...
Sep 08, 2021 02:28 pm ET
ANVS CLASS ACTION DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Annovis Bio, Inc.
NEW YORK, Sept. 8, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit filed on behalf of investors who purchased or acquired the securities of Annovis Bio, Inc.. ("Annovis Bio" or the "Company") (NYSE: ANVS) from May 21, 2021 through July 28, 2021 (the "Class Period"). The lawsuit filed in the United States District Court for the Eastern District of Pennsylvania alleges violations of the Securities Act of 1934.
Sep 07, 2021 10:37 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of ANVS, ATVI and ZY
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. Activision Blizzard, Inc. (ATVI)Class Period: August 4, 2016 and July 27, 2021Lead Plaintiff Motion Deadline:...
Sep 07, 2021 12:05 pm ET
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Annovis Bio, Inc. (ANVS) Investors
LOS ANGELES, Sept. 7, 2021 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Annovis Bio, Inc. ("Annovis" or the "Company") (NYSE: ANVS) securities between May 21, 2021 and July 28, 2021, inclusive (the "Class Period"). Annovis investors have until October 18, 2021 to file a lead plaintiff motion.
Sep 06, 2021 10:23 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS ATVI, ZY, ANVS, SESN INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Activision Blizzard, Inc. (ATVI)Class Period: 8/4/2016 - 7/27/2021Lead Plaintiff Motion Deadline:...
Sep 05, 2021 04:15 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Annovis Bio, Inc. - ANVS
NEW YORK, Sept. 5, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Annovis Bio, Inc. ("Annovis" or the "Company") (NYSE: ANVS). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Sep 03, 2021 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS ANVS, ATVI, SESN, ZY INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Activision Blizzard, Inc. (ATVI)Class Period:...
Sep 03, 2021 03:51 pm ET
INVESTOR ALERT: Kirby McInerney LLP Reminds Investors That a Securities Class Action Lawsuit Has Been Filed on Behalf of Annovis Bio, Inc. (ANVS) Investors and Encourages Investors to Contact the Firm
The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Eastern District of Pennsylvania on behalf of those who acquired Annovis Bio, Inc. (“Annovis” or the “Company”)...
Sep 03, 2021 01:00 pm ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Annovis Bio, Inc. (ANVS)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming October 18, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Annovis Bio, Inc. (“Annovis” or the...
Sep 03, 2021 11:45 am ET
DEADLINE ALERT for ANVS, VIEW, and SESN: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Sep 03, 2021 08:30 am ET
Annovis Bio Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)
Berwyn, Pennsylvania--(Newsfile Corp. - September 3, 2021) - Annovis Bio, Inc. (NYSE American: ANVS), a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease (AD), Parkinson's disease (PD) and Alzheimer's in Down Syndrome (AD-DS), today announced that an interview with CEO and President Dr. Maria Maccecchini, Ph.D. will air on The RedChip Money Report on Bloomberg US on this Saturday September 4th at 7 p.m. Eastern Time. Bloomberg TV is available in an estimated 73 million homes across the United States.
Sep 02, 2021 07:13 pm ET
Class Action Lawsuit Deadline: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Annovis Bio, Inc.
The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States District Court for the Eastern District of Pennsylvania against Annovis Bio, Inc. (NYSE: ANVS) (“Annovis”)...
Sep 01, 2021 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS ANVS, ATVI, SESN, ZY INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Activision Blizzard, Inc. (ATVI)Class Period: 8/4/2016 - 7/27/2021Lead Plaintiff Motion Deadline:...
Sep 01, 2021 08:36 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against DiDi, Live Ventures, and Annovis Bio and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of DiDi Global Inc. (NYSE: DIDI), Live Ventures Incorporated (NASDAQ: LIVE) and...
Aug 31, 2021 11:01 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of ANVS, ATVI, SESN and ZY
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. Activision Blizzard, Inc. (ATVI)Class Period: August 4, 2016 and July 27, 2021Lead Plaintiff Motion Deadline:...
Aug 31, 2021 01:00 pm ET
DEADLINE ALERT for SLQT, PHG, ANVS, VIEW: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Aug 30, 2021 10:50 pm ET
INVESTOR ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action Lawsuits filed on behalf of ANVS, ATVI, SESN, ZY Investors, Lead Plaintiff Deadlines Set
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Activision Blizzard, Inc. (ATVI)Class Period:...
Aug 30, 2021 04:00 pm ET
LAWSUIT FILED: ANNOVIS BIO Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information
Block & Leviton announces that a class action lawsuit has been filed against Annovis Bio Inc. (NYSE: ANVS) and certain of its officers for securities law violations. Investors who purchased shares between May 21, 2021 and July 28, 2021 and have...
Aug 28, 2021 11:03 am ET
ANVS CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Annovis Bio, Inc. Shareholders of Securities Fraud Class Action Lawsuit
The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed against Annovis Bio, Inc. (NYSE: ANVS) (“Annovis”) on behalf of those who purchased or acquired Annovis securities between May 21, 2021 and July 28, 2021, inclusive (the “Class Period”).
Aug 27, 2021 10:50 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS ANVS, ATVI, SESN, ZY INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Activision Blizzard, Inc. (ATVI)Class Period: 8/4/2016 - 7/27/2021Lead Plaintiff Motion Deadline:...
Aug 27, 2021 05:45 pm ET
ROSEN, A TOP RANKED LAW FIRM, Encourages Annovis Bio, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – ANVS
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Annovis Bio, Inc. (NYSE: ANVS) between May 21, 2021 and July 28, 2021, inclusive (the “Class Period”), of the important October 18, 2021 lead plaintiff...
Aug 27, 2021 03:58 pm ET
Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Lawsuit Filed Against Annovis Bio, Inc.
RADNOR, Pa., Aug. 27, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed against Annovis Bio, Inc. (NYSE: ANVS) ("Annovis") on behalf of those who purchased or acquired Annovis securities betweeen May 21, 2021 and July 28, 2021, inclusive (the "Class Period").
Aug 27, 2021 03:45 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Annovis Bio, Inc. - ANVS
NEW YORK, Aug. 27, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Annovis Bio, Inc. ("Annovis" or the "Company") (NYSE: ANVS).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Aug 27, 2021 12:07 pm ET
DEADLINE ALERT for ANVS, VIEW, and SESN: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Aug 26, 2021 04:52 pm ET
Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Filed Against Annovis Bio, Inc. – ANVS
The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States District Court for the Eastern District of Pennsylvania against Annovis Bio, Inc. (NYSE: ANVS) (“Annovis”)...
Aug 26, 2021 01:46 pm ET
ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages Annovis Bio, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline in Securities Class Action – ANVS
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Annovis Bio, Inc. (NYSE American: ANVS) between May 21, 2021 and July 28, 2021, inclusive (the “Class Period”), of the important October 18, 2021 lead plaintiff deadline.
Aug 26, 2021 12:00 pm ET
INVESTOR ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Annovis Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, Aug. 26, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Annovis Bio, Inc. ("Annovis" or "the Company") (NYSE: ANVS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Aug 26, 2021 11:00 am ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Annovis Bio, Inc. (ANVS)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming October 18, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Annovis Bio, Inc. (“Annovis” or...
Aug 25, 2021 10:26 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS ANVS, ATVI, SESN, ZY INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Activision Blizzard, Inc. (ATVI)Class Period:...
Aug 25, 2021 08:37 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against DiDi, RenovaCare, Live Ventures, and Annovis Bio and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of DiDi Global Inc. (NYSE: DIDI), RenovaCare, Inc. (Other OTC: RCAR), Live Ventures...
Aug 25, 2021 08:00 pm ET
ANVS NOTICE: Investors With Substantial Losses Have Opportunity to Lead the Annovis Bio, Inc. Class Action Lawsuit
SAN DIEGO, Aug. 25, 2021 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers of Annovis Bio, Inc. (NYSE: ANVS) securities between May 21, 2021 and July 28, 2021, inclusive (the "Class Period"), have until October 18, 2021 to seek appointment as lead plaintiff in the Annovis Bio class action lawsuit.  The Annovis Bio class action lawsuit (Zhou v. Annovis Bio, Inc., No. 21-cv-03668) charges Annovis Bio and certain of its top executives with violations of the Securities Exchange Act of 1934.  The Annovis Bio class action lawsuit was commenced on August 17, 2021 in the
Aug 25, 2021 11:00 am ET
ANVS Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Annovis Bio, Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm
Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Annovis Bio, Inc. (“Annovis” or the “Company”) (NYSE: ANVS) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Annovis securities between May 21, 2021 and July 28, 2021, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site:
Aug 25, 2021 09:11 am ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Annovis Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Annovis Bio, Inc. (“Annovis” or “the Company”) (NYSE:
Aug 25, 2021 08:30 am ET
Annovis Bio to Present at Biomarkers for Alzheimer's Disease Summit 2021
Berwyn, Pennsylvania--(Newsfile Corp. - August 25, 2021) - Annovis, Bio, Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, announced today that Maria Maccecchini, PhD, Founder, CEO and President of Annovis Bio, will present at the Biomarkers for Alzheimer's Disease Summit 2021, held on August 25 and 26, 2021.
Aug 25, 2021 12:09 am ET
Portnoy Law: Lawsuit Filed On Behalf of Annovis Bio, Inc. Investors
​The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Annovis Bio, Inc. ("Annovis" or "the Company") (NYSE : ANVS) investors that acquired securities between May 21, 2021 and July 28, 2021. Investors are...
Aug 24, 2021 10:50 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of ANVS, ATVI, PYPL and RKT
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. Rocket Companies, Inc. (RKT)Class Period: February 25, 2021 and May 5, 2021Lead Plaintiff Motion Deadline: August...
Aug 23, 2021 11:32 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of San Juan Basin Royalty Trust - SJT
NEW YORK, Aug. 23, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of San Juan Basin Royalty Trust ("SJB" or the "Trust") (NYSE: ANVS). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Aug 23, 2021 10:50 pm ET
ANVS, ATVI, ZY INVESTOR ALERT: CLAIMSFILER REMINDS SHAREHOLDERS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Activision Blizzard, Inc. (ATVI)Class Period: 8/4/2016 - 7/27/2021Lead Plaintiff Motion Deadline:...
Aug 23, 2021 04:10 pm ET
Investors With Substantial Losses Have Opportunity to Lead the Annovis Bio, Inc. Class Action Lawsuit – ANVS
Robbins Geller Rudman & Dowd LLP announces that purchasers of Annovis Bio, Inc. (NYSE: ANVS) securities between May 21, 2021 and July 28, 2021, inclusive (the “Class Period”), have until October 16, 2021 to seek appointment as lead plaintiff in the Annovis Bio class action
Aug 23, 2021 11:00 am ET
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Annovis Bio, Inc. (ANVS)
Law Offices of Howard G. Smith reminds investors of the upcoming October 18, 2021 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Annovis Bio, Inc. (“Annovis” or the “Company”) (NYSE: ANVS) securities between May 21, 2021 and July 28, 2021, inclusive (the “Class Period”
Aug 23, 2021 10:00 am ET
ANVS Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Annovis Bio, Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Annovis Bio, Inc. (“Annovis” or the “Company”) (NYSE: ANVS) and certain of its officers, on behalf of shareholders who...
Aug 21, 2021 01:23 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Annovis Bio, Inc. - ANVS
Pomerantz LLP is investigating claims on behalf of investors of Annovis Bio, Inc. (“Annovis” or the “Company”) (NYSE: ANVS). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Aug 20, 2021 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS ANVS, ATVI, ZY INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Activision Blizzard, Inc. (ATVI)Class Period:...
Aug 20, 2021 06:09 pm ET
INVESTOR ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Annovis Bio, Inc. (ANVS) Investors
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Eastern District of Pennsylvania on behalf of those who acquired Annovis Bio, Inc. (“Annovis” or the “Company”) (NYSE:

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.